top of page

Search

Mar 13, 20231 min read

TECHNOLOGY DEVELOPMENT

Reaction Biology GmbH will collaborate in developiment of a specific PKM2 assay for ONKONEK activity in human cancers.

Recent Posts

The patent describing ONKONEK's unique cancer-killing warhead has just been granted in Europe.

Selectively depleting the energy of cancer cells: A new therapeutic paradigm

ESSENTIAL MOLECULAR

Comments

bottom of page